Lysosomal Disease Treatments Market

Lysosomal Disease Treatments Market: Introduction

Lysosomal storage disorders cause several diseases. Lysosomal storage diseases (LSDs) are a large group of disorders caused by a deficiency of specific enzymes responsible for the degradation of substances present in lysosomes. They affect the lysosome -- a structure in cells that breaks down substances, such as proteins, carbohydrates, and old cell parts so the body can recycle them. The purpose of substrate reduction therapy is to down regulate the formation of the lysosomal substance to a rate at which the residual enzyme activity can catabolize the stored and de novo produced lysosomal substrate. Chemical chaperone therapy is based on small molecules able to bind and stabilize the misfolded enzymes.

Clinical signs characterizing different diseases depend on the quantity and type of accumulated substance; in general, the disease is named after the type of undegraded substrate. Most LSDs have an autosomal recessive inheritance pattern. Mucopolysaccharidosis type II, Fabry disease, and Danon disease are X-linked. Different therapeutic approaches were used in the past to address the underlying causes of the diseases: infusion of plasma or plasma fractions, intravenous injection of exogenous enzymes extracted from human tissues, infusion of leukocytes and implantation of skin fibroblasts or amniotic cells. People with these disorders are missing important enzymes (proteins that speed up reactions in the body). Without the enzymes, the lysosome is not able to break down these substances.

Key Drivers of Global Lysosomal Disease Treatments Market

Demand for orphan drug status

• Current economic situation, along with growing generic competition has shifted the focus of pharmaceutical companies from essential medicines to a new business model - niche busters, also called orphan drugs
• Orphan drugs may help pharma companies to reduce the impact of revenue loss caused by patent expiries of blockbuster drugs
• Rare diseases in small patient population, thus “orphaned” by the pharmaceutical industry having but a few approved drug treatment options available are called orphan diseases
• Orphan diseases are often so rare that a physician may observe only one case a year or less. Academic physician-scientists have tried to fill this therapy vacuum by working on developing orphan drugs.

North America to Hold Major Share of Global Lysosomal Disease Treatments Market

• North America is expected to hold a major share of the global lysosomal disease treatments market during the forecast period. The market in North America is estimated to expand at a rapid pace in the near future, primarily due to structured reimbursement policies, increase in prevalence of obesity & cardiovascular diseases, developed health care infrastructure, and continuous research activities in developing advanced technologies in North America.
• Lysosomal disease treatments market in Asia Pacific is projected to expand at a rapid pace during the forecast period. This can be attributed to growing trend of preventive health care measures.

Key Players Operating in Global Market

The global lysosomal disease treatments market is highly concentrated due to the presence of a few key players. Several manufacturers hold major share of the market in their respective regions. Leading players operating in the global lysosomal disease treatments market are:

• Shire PLC
• Pfizer, Inc.
• Sanofi
• BioMarin Pharmaceutical Inc.
• Actelion Ltd.
• Raptor Pharmaceutical Corp.
• Protalix Biotherapeutics Inc.
• Amicus Therapeutics, Inc.

Global Lysosomal Disease Treatments Market: Research Scope

Global Lysosomal Disease Treatments Market, by Indication

• Aucher's Diseases
• Fabry Diseases
• Pompe’s Syndrome
• Mucopolysaccharidosis
• Others

Global Lysosomal Disease Treatments Market, by Type of Therapy

• Enzyme Replacement Therapy
• Stem Cell Therapy
• Substrate Reduction Therapy
• Others

Global Lysosomal Disease Treatments Market, by End-user

• Clinics
• Hospitals
• Others

Global Lysosomal Disease Treatments Market, by Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
• Asia Pacific
  • China
  • Japan
  • India
  • Australia & New Zealand
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa